Alterity Therapeutics Ltd
ATHE3.848USD
-0.052-1.33%
Horário de mercado （ET）Cotações atrasadas em 15 min
58.54MValor de mercado
--P/L TTM
Mais detalhes de Alterity Therapeutics Ltd Empresa
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Informações de Alterity Therapeutics Ltd
Código da empresaATHE
Nome da EmpresaAlterity Therapeutics Ltd
Data de listagemMar 28, 2000
CEODr. David A. Stamler, M.D.
Número de funcionários9
Tipo de títulosDepository Receipt
Fim do ano fiscalMar 28
EndereçoL 3 460 Bourke St
CidadeMELBOURNE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísAustralia
Código postal3000
Telefone61393494906
Sitehttps://alteritytherapeutics.com/
Código da empresaATHE
Data de listagemMar 28, 2000
CEODr. David A. Stamler, M.D.
Executivos da empresa Alterity Therapeutics Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 24 de out
Atualizado em: sex, 24 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Twin Lakes Capital
0.77%
Point72 Asset Management, L.P.
0.73%
Homrich Berg
0.32%
Morgan Stanley & Co. LLC
0.32%
Greenleaf Trust
0.18%
Outro
97.69%
Investidores
Investidores
Proporção
Twin Lakes Capital
0.77%
Point72 Asset Management, L.P.
0.73%
Homrich Berg
0.32%
Morgan Stanley & Co. LLC
0.32%
Greenleaf Trust
0.18%
Outro
97.69%
Tipos de investidores
Investidores
Proporção
Private Equity
0.77%
Hedge Fund
0.73%
Research Firm
0.37%
Investment Advisor/Hedge Fund
0.33%
Bank and Trust
0.18%
Outro
97.63%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
27
429.83K
2.37%
+138.63K
2025Q2
25
222.41K
1.45%
+22.59K
2025Q1
25
242.89K
1.60%
+14.64K
2024Q4
25
125.35K
1.13%
-75.38K
2024Q3
25
113.89K
1.28%
-62.37K
2024Q2
24
79.19K
0.91%
-96.76K
2024Q1
24
95.17K
1.09%
-51.08K
2023Q4
23
88.25K
1.89%
-31.21K
2023Q3
26
59.08K
1.45%
-63.37K
2023Q2
27
58.44K
1.44%
-90.15K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Twin Lakes Capital
5.92K
0.03%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
131.43K
0.73%
--
--
Jun 30, 2025
Homrich Berg
--
0%
-37.48K
-100.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
58.23K
0.32%
+14.60K
+33.46%
Jun 30, 2025
Greenleaf Trust
17.00K
0.09%
+17.00K
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
8.19K
0.05%
-1.56K
-16.02%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.16K
0.01%
--
--
Aug 31, 2025
EverSource Wealth Advisors, LLC
628.00
0%
+628.00
--
Jun 30, 2025
Osaic Holdings, Inc.
181.00
0%
--
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
130.00
0%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Data
Tipo
Proporção
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
Dec 30, 2022
Merger
10→1
